Tag Archives: regenerative medicine

Regenexx Announces the Publication of “Orthopedics 2.0 – How Regenerative Medicine and Interventional Orthopedics will Change Everything” on Amazon Kindle

Broomfield, CO, February 02, 2015 — /EPR BIOTECH NEWS/ — With more than 40,000 downloads, “Orthopedics 2.0 – How Regenerative Medicine and Interventional Orthopedics will Change Everything” is now available on Amazon Kindle. The third edition of the top-selling e-book is being offered as a free download through Jan. 6, 2015.

Written by Dr. Chris Centeno, this e-book delves into the human musculoskeletal system and explains how everything works together in concert to maintain our physical wellbeing. When a single component in this chain is damaged, it can lead to a cascade of joint, spine and connective tissue problems, resulting in chronic pain.

Using the Regenexx SANS approach, Orthopedics 2.0 walks you through a series of tests and exercises that you can do on your own to better understand where your own body is struggling to maintain proper stability and alignment, explaining the possible reasons and long term implications along the way. Orthopedics 2.0 also explores how Regenexx is pioneering the new field of Interventional Orthopedics, where the use of regenerative biologic treatments, such as adult stem cell therapy and platelet rich plasma, are being used to help repair and strengthen damaged tissues, as opposed to invasive surgeries that often remove important tissues when a joint or the spine becomes damaged.

With hyperlinks to more detailed information, related studies and commentary, this book condenses a vast amount of data and resources into an enjoyable and entertaining read.

About Regenexx
Since its genesis in 2005, Regenexx has been a world-leader in the use of adult stem cell treatments for orthopedic conditions, providing non-surgical, biologic therapies delivered with high accuracy through a needle. Regenexx has collected and published more data on stem cell patients than any other company and are dedicated to reinventing orthopedic care to help patients avoid invasive surgery.

Featured on television and media outlets such as the Doctors TV show, ABC News, Good Morning America and many others, Regenexx is taking orthopedic stem cell therapy to an exciting new level.

For more information about this e-book or to talk with a Regenexx Liaison, please call 888-525-3005 or email info@regenexx.com. Visit Regenexx online at:http://www.regenexx.com/

Contact-Details: Regenexx
Contact: Mark Testa
403 Summit Blvd., Suite 201
Broomfield, CO 80021
Phone: 888.525.3005
Email: info@regenexx.com
Web – http://www.regenexx.com/

Via EPR Network
More Biotech press releases

MicroTissues, Inc.’s 3D Petri Dish™ Is Helping to Reduce Animal Use in Research

MicroTissues, Inc. announced today that its 3D Petri Dish™ is targeted towards helping to reduce the numbers of animals used in research. The 3D Petri Dish™ is a new tool for the world wide industry of life sciences research and drug discovery that grows living cells in three dimensions (3D). These 3D microtissues replicate the function of natural tissues and organs better than conventional 2D methods and are increasingly being used in toxicity testing of new drugs and cosmetics.

“Worldwide, efforts are underway to reduce the use of animals in research and we’re excited to be offering a new technology for toxicity testing” said Brian Morgan, Marketing Manager of MicroTissues, Inc. “The 3D Petri Dish™ is a reliable 3D cell culture technology that accurately produces natural cell-to-cell interactions and is easy to use. And, it forms 3D microtissues from human cells, so toxicity testing data is more relevant.”

Effective 2009, the European Union banned the use of animal testing for cosmetic products and many believe the trend to reduce the use of animals in research will continue worldwide. MicroTissues, Inc. is helping to address this issue by offering eight products that are precision micro-molds used to cast 3D Petri Dishes™ that fit in standard multi-well plates. The 3D Petri Dish™ forms hundreds of multi-cellular 3D spheroids from cells useful for toxicity testing including hepatospheres, cardiospheres, mammospheres, neurospheres, and embryoid bodies. The 3D Petri Dish™ technology also forms microtissues with complex shapes having geometries that mimic natural organs. Over thirty different cell types, including primary human cells, have been shown to form 3D microtissues in the 3D Petri Dish™.

MicroTissues, Inc. a privately held company with an exclusive worldwide license to US and international patent applications on the 3D Petri Dish™, is advancing technologies and applications of 3D cell culture. The company’s products stand above the rest because they are designed to create more natural and more reliable 3D cell culture environments based on cell-to-cell interactions in convenient and consistent formats that generate high content information. The company’s lead line of products, the 3D Petri Dish™, is serving the needs of researchers in a wide range of areas including cancer research, stem cell biology, toxicity testing, developmental biology, drug discovery, regenerative medicine and tissue engineering. In addition to products for basic research, MicroTissues, Inc. is using its platform technology to pursue applications in drug discovery and cell therapy. For more information, please visit www.microtissues.com.

Via EPR Network
More Biotech press releases